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Abstract
Diagnosing and treating hypertension plays an important role in minimising the risk of cardiovascular disease and
stroke. Early and accurate diagnosis of hypertension, as well as regular monitoring, is essential to meet treatment
targets. In this article, current recommendations for the screening and diagnosis of hypertension are reviewed. The
evidence for treatment targets specified in contemporary guidelines is evaluated and recommendations from the
USA, Canada, Europe and the UK are compared. Finally, consideration is given as to how diagnosis and management
of hypertension might develop in the future.
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Background
Hypertension affects around 40 % of the worldwide
population aged over 25 years, and is estimated to be
implicated in approximately half of the deaths from
stroke or cardiovascular disease [1]. Early and accurate
diagnosis is essential in order to appropriately manage
hypertension and reduce these risks, but national and
international surveys suggest that many people continue
to have unrecognised or untreated hypertension, with
variation between countries [2, 3]. Here, the evidence on
screening and diagnosis of hypertension is reviewed and
consideration given as to optimum treatment targets for
preventing cardiovascular disease in patients.
What is the best way to diagnose hypertension?
Traditionally, hypertension has been diagnosed using
clinic blood pressure (BP) measurements, typically tak-
ing several readings on several occasions and then treat-
ing those whose mean BP is consistently above the
diagnostic threshold [4–6]. However, since the advent of
both ambulatory blood pressure monitoring (ABPM)
and self-measured blood pressure (SMBP), it has been
recognised that measurements outside of a clinic en-
vironment are better correlated with long-term out-
comes [7–11].
ABPM is widely regarded as the “gold standard” for
BP measurement. For example, both the Dublin out-
come study, involving 5,292 patients, and a meta-
analysis of 7,030 individuals from the International
Database of Ambulatory Blood Pressure in relation to
Cardiovascular Outcome (IDACO) database, found that
systolic and diastolic ABPM measurements significantly
and independently predicted cardiovascular outcomes
over and above clinic BP [12, 13]. Furthermore, the
Ohasama study (1,464 subjects, general population, 6- to
9-year follow-up), found that mean ambulatory pressure,
especially mean daytime, was linearly related to stroke
risk and was a stronger predictor than clinic BP [14].
Other measures of blood pressure, particularly nighttime
pressure, have been suggested as superior but may not
add much more in terms of prognosis than the 24-hour
mean itself [15]. ABPM also allows identification of
masked and white coat hypertension and is reprodu-
cible [16–19]. Masked hypertension carries significant
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cardiovascular risk [20], which is estimated to be
similar to sustained hypertension [21, 22].
There is also strong evidence for the prognostic accur-
acy of SMBP over clinic BP. SMBP is a significantly stron-
ger predictor of cardiovascular outcomes [11, 23, 24],
stroke [25, 26] and target organ damage [24, 27] than
clinic BP. A recent systematic review found that the asso-
ciation of SMBP with target organ damage was as strong
as that from ABPM [28].
Very few studies have assessed SMBP, ABPM and
clinic BP against each other for cardiovascular outcomes.
Fagard et al. compared these three methods of BP meas-
urement for predicting cardiovascular events over
10 years in 391 older patients [29]. The authors found
that the prognostic value of self-monitoring and daytime
ABPM were similar to office measurements in predicting
cardiovascular outcomes, but the strongest independent
predictor was nighttime ABPM.
In a systematic review, Hodgkinson et al. evaluated 20
studies that had made a hypertension diagnosis with
clinic or home BP measurement compared to ABPM as
reference standard [30]. Using a clinic diagnostic thresh-
old of 140/90 mmHg and ambulatory and self-
monitoring thresholds of 135/85 mmHg, the review
found neither home nor clinic measurements to be suffi-
ciently accurate compared to ABPM, although others
have argued that BP differences for those with discord-
ant ABPM and self-monitoring are small [31, 32]. Fur-
thermore, only three SMBP studies were available at the
time. Since then, a number of other studies have been
reported, including Nasothimiou [31] and Nunan [33].
The former studied patients attending a hypertension
clinic and recorded high diagnostic test performance for
self- compared to ambulatory monitoring, whereas
Nunan’s paper reported high sensitivity and only modest
specificity, but utilised a community-based cohort with a
lower prevalence of sustained hypertension (54 % versus
65 % in untreated subjects).
Current diagnostic thresholds for out-of-office meas-
urement are based on work by Head et al., which com-
pared 8,575 ABPM measurements to contemporaneous
clinic readings taken by trained staff [34]. They found
that the equivalent daytime mean ABPM for an office
measurement of 140/90 mmHg was 4/3 mmHg less,
which led to an ABPM target of 135/85 mmHg. How-
ever, work by Niiranen et al. suggested that the thresh-
olds for SMBP are different and systolic thresholds in
particular may be too high [35]. Based on a hypertensive
population, Niiranen et al. found that thresholds of
130/85 and 145/90 mmHg for stages 1 and 2 hyper-
tension better predicted outcomes for cardiovascular
events over an 8-year follow-up.
A strong argument for using out-of-office measures
arises from the concept of masked hypertension, where
patients have a normal or controlled clinic BP but an
elevated out-of-office measurement. Diagnosis of this
condition is important because patients can be untreated
or undertreated putting them at greater risk of cardio-
vascular disease [21]. Banegas et al. analysed data from
the Spanish Society of Hypertension ABPM registry [36].
Out of more than 14,000 patients, with treated and
(apparently) controlled clinic BP, 31.1 % had masked un-
controlled hypertension, with the most likely reason be-
ing poor control of nighttime BP. Both ABPM and
SMBP offer a way to diagnose and manage masked
hypertension, but only if performed routinely in those
with normal clinic BP. Hence more work needs to be
carried out to understand the best way to target patients
appropriately and manage masked hypertension in the
longer term.
The cost-effectiveness of routine out-of-office meas-
urement in the diagnosis of hypertension was assessed
in a modelling exercise undertaken as part of the devel-
opment of the National Institute for Health and Care
Excellence (NICE) hypertension guideline [37]. This
showed that the additional costs of ABPM were more
than offset by the increased precision in diagnosis,
and hence it was more cost-effective than either office
BP measurement or SMBP for all age and gender
subgroups. Long-term costs (in terms of cardiovascu-
lar events and reduced need for follow-up) were re-
duced when using ABPM instead of office BP
measurement. There are potential issues with ABPM,
including availability and feasibility [5]. However,
given the need for life-long treatment following a
diagnosis of hypertension, these are arguably insuffi-
cient to prevent implementation – a fact underpinned
by the recent Canadian recommendations [38].
New technologies may provide a useful interface be-
tween non-physician screening and primary care. Tele-
monitoring and electronic submission of readings are
becoming more popular [39] and, with smartphones be-
coming ever more sophisticated, it seems likely that this
will play a role in diagnosing and managing hypertension
in the future. There is growing evidence that telemoni-
toring in combination with self-monitoring is more
effective than usual care in reducing blood pressure [40]
and is acceptable to patients [41]. However, it is not
widely used in clinical practice. The barriers to using
telemonitoring include the initial set-up costs and issues
around reimbursement.
A recent randomised controlled trial (RCT) using
telemonitoring in the UK found that the direct mean
cost of systolic BP reduction was £25.56/mmHg per
patient compared to usual care [42]. Even though the
telemonitoring intervention significantly reduced BP
over 6 months, unless longer-term outcomes (cardio-
vascular events) are considered, the additional costs
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of telemonitoring may not be considered affordable.
There are also differences between healthcare and tel-
emonitoring systems, which can lead to apparently
contradictory results, with some found to be cost-
effective [43–45] but others not [46].
Another barrier, particularly significant to the USA, is
the need for uniform quality standards which drive reim-
bursement. There is a lack of acceptance that patient-
reported data meets quality measures, which stipulate
that controls, such as face-to-face visits and physiologic
measurements, adhere to certain specifications, for
example nurse-only BP checks [47]. In theory, telemoni-
toring could fulfil these criteria and the American
Telehealth Association is working to address such bar-
riers and start implementing telehealth in primary care
[48]. As the evidence base for using telemonitoring in
primary care continues to expand, it is likely that we will
start to see guidelines and standards for telemonitoring
in the UK and Europe as well.
When should patients have their BP measured?
In addition to the method of screening for hypertension,
the frequency of such screening is also important, but
the evidence to underpin this is scarce. Piper et al. tried
to confirm “the shortest interval in which clinically sig-
nificant, diagnosed hypertension may develop” in their
recent systematic review [49]. They found 43 studies had
examined screening intervals and established the inci-
dence of hypertension found in 1- to 5-year intervals. It
was impossible to reach any firm conclusions due to het-
erogeneity in the study results, with mean incidence ran-
ging from 2 % to 28 % over a 5-year period [49]. It may
be more helpful to consider when to rescreen on the
basis of current BP. Five studies reported on the inci-
dence of hypertension over a 5-year period for three
categories of BP: optimum, <120/80 mmHg; normal,
120–129/80–84 mmHg; and high-normal, 130–139/85–
89 mmHg [50–54]. Meta-analysis showed increased inci-
dence of hypertension with increasing baseline blood
pressure, a six-fold increase between high-normal and
optimum, and a very low rate in the latter case – of less
than 10 % in a 5-year period [49]. The authors suggest
that this highlights the need to identify subpopulations
which may benefit from a more structured screening
programme, including older people, overweight or obese
patients, those with a high-normal BP and certain ethnic
minority groups [49].
Whilst primary care remains the commonest setting
for hypertension screening, there is growing evidence to
suggest that community screening may help to reach
greater numbers of patients. A comprehensive system-
atic review by Fleming et al. showed that screening has
been undertaken in a range of locations, with pharma-
cies and mobile units the most successful settings
assessed, albeit with a high level of heterogeneity [55].
However, only 16 % of studies reported a referral to pri-
mary care following screening, of which a new hyperten-
sion diagnosis was made in a median of 44 %, suggesting
that a joined-up approach is fundamental to the impact
of such screening.
Novel primary care settings may also prove successful,
such as optometry [56]. In the USA, screening for med-
ical conditions in dentistry has been assessed as poten-
tially acceptable to both patients and physicians [57, 58].
More studies in this area are needed to establish how
physician and non-physician screening could comple-
ment each other.
Recently, a group of primary care practices in the USA
developed an algorithm for identifying patients at risk of
hypertension from their electronic records [59]. The
innovation was successful and has now been imple-
mented in these practices. It is easy to see how this type
of innovation could be used in calculating rescreening
intervals for patients and also follow-up times after BP
treatment intensification.
Where and how are patients currently diagnosed?
Since 2011, in the UK, guidelines from NICE have
recommended that a raised clinic BP reading (≥140/
90 mmHg) in an undiagnosed patient should be followed
by confirmatory ABPM, unless BP ≥180/110 mmHg
[37]. Home BP measurement can be used as an alterna-
tive if ABPM is not available or tolerated.
In comparison, the European Society of Hypertension
(ESH) practice guidelines (2013) recommend that office
BP remains the “gold standard” for screening, diagnosis
and management of hypertension [60]. However, for
diagnostic purposes they recommend that ABPM or
home BP is used in the case of suspected white coat
hypertension, masked hypertension, grade I hypertension
(≥140/90 mmHg) and high-normal BP, which can be
interpreted as a broad recommendation for use.
The Canadian Hypertension Education Program
(CHEP) have recently updated their recommendations
for the diagnosis of hypertension to include the use of
ABPM and home BP monitoring [61]. For any office BP
measurement >140/90 mmHg but <180/110 mmHg,
out-of-office measurement should be used to rule out
white coat hypertension. ABPM readings should be
taken every 20–30 minutes during the day and every
30–60 minutes at night. At least 20 daytime readings
and 7 nighttime readings are required to obtain an ac-
curate average reading. Home BP should be measured
using validated monitors that have met the standards set
by the Association for the Advancement of Medical
Instrumentation (AAMI). Hypertension diagnoses using
home monitoring should be based on duplicate mea-
surements taken morning and evening for a 7-day
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period, with the first day discarded. A diagnostic target
of ≥135/85 mmHg is recommended for all out-of-office
measurements [38]. In the USA, the Eighth Joint
National Committee (JNC 8) report updated the thresh-
old for a diagnosis of hypertension in those aged 60 years
and over, and those with diabetes or chronic kidney dis-
ease, but maintained previous recommendations on the
use of clinic BP for routine diagnosis of hypertension
[62]. More recent evidence reviews in America have rec-
ommended updating guidelines to include ABPM for all
new diagnoses of hypertension and as a way of quickly
diagnosing white coat or masked hypertension. Overall,
the direction of travel in guidelines in Europe and
North America is firmly towards greater use of out-
of-office measurement of BP in the diagnosis of
hypertension [49, 63].
What is the evidence for treatment targets in
hypertension?
Although it can be argued that the relationship between
BP and cardiovascular risk is continuous, hypertension
targets provide an essential management guide [64]. The
Hypertension Optimal Treatment (HOT) trial, which
compared three diastolic targets (≤90 mmHg, ≤85 mmHg
and ≤80 mmHg), tried to provide definitive data and
found no difference overall in the rate of cardiovascu-
lar events between targets [65]. Interestingly, there
was a 51 % reduction in cardiovascular events be-
tween the ≤90 mmHg target group and ≤80 mmHg
target group in diabetic patients, highlighting the
need to consider different targets depending on the
level of cardiovascular risk. Furthermore, post hoc
analyses suggested that the lowest incidence of car-
diovascular events was at 82.6 mmHg, whilst the low-
est mortality rate was at 86.5 mmHg, and the small
differences in achieved BP between groups have been
criticised [65]. The use of diastolic targets has declined
more recently with the evidence that systolic BP carries
the greatest risk for heart disease and stroke, and this is
reflected in most current guidelines [66, 67].
Over the last decade, work to establish accurate BP
targets for treatment has been ongoing. A comprehen-
sive meta-analysis by Law et al. reported a fall in cardio-
vascular disease (CVD) events by 25 %, a reduction in
heart failure by about 25 % and in stroke by 33 % for
every 10 mmHg drop in systolic BP and every 5 mmHg
drop in diastolic BP without a lower threshold, at least
to 110 mmHg systolic [68]. A recent individual patient
data meta-analysis by the Blood Pressure Lowering
Treatment Trialists’ Collaboration included over 50,000
patients and showed that lowering BP provided a similar
relative risk reduction for all levels of cardiovascular risk
[69]. However, the absolute risk reduction increased as
the level of cardiovascular risk increased. For every
1,000 patients with >20 % cardiovascular risk, 38 CVD
events could be prevented over 5 years, whereas for
every 1,000 patients with a 6 % cardiovascular risk, 14
CVD events would be prevented. Therefore, patients at
the highest risk stand to gain the most from having their
BP lowered and arguably might benefit from lower tar-
gets [69]. Despite this, trials have failed to show benefit
from intensive lowering of BP, particularly for older pa-
tients. The Valsartan in Elderly Isolated Systolic Hyperten-
sion (VALISH) study assessed a BP target of <140 mmHg
against a more relaxed target of ≥140–150 mmHg in pa-
tients aged 70 years or older [70]. After 3 years, the num-
ber of composite cardiovascular events between the two
target groups was not significant, although rather
counterintuitively the authors concluded that the more
stringent target was safe to initiate in older patients [70].
The Japanese Trial to Assess Optimal Systolic Blood
Pressure in Elderly Hypertensive Patients (JATOS), which
looked at the optimum systolic BP target in elderly hyper-
tensive patients, also found no difference in cardiovascular
disease or renal failure between patients with a systolic
pressure ≤140 mmHg and those with a target ≤160 mmHg
[71]. There was also no difference in mortality or adverse
events between the groups. However, as the endpoints of
both these trials were less frequent than expected, both
were ultimately underpowered to answer whether tighter
BP control was in fact superior to a more relaxed BP
target.
The modelling work of Port et al. contradicts the epi-
demiological and trial evidence [64, 72] finding that the
risk of CVD, stroke and death is stable below a cut-off at
the 70th centile, with age- and sex-dependent increases
in risk above this [73]. According to the thresholds pro-
posed by Port et al., patients with a BP of 155 mmHg
would not be treated. This suggestion has not been
taken up internationally by guideline developers, other
than for the elderly where the Hypertension in the Very
Elderly Trial (HYVET) provided strong evidence for a
similar treatment target [74], although Port's work has
the potential merit of targeting treatment to younger
high relative risk individuals.
Recent work examining the effectiveness of BP targets
in a treated hypertension population of 398,419 has
shown the presence of a J-shaped curve, where the high-
est rate of mortality came from lower and higher BP
than the reference standard of 130–139/60–79 mmHg.
The nadir for systolic and diastolic BP was 137/
69 mmHg, but stratified analysis for patients with dia-
betes showed that the nadir was slightly lower at 131/
69 mmHg, while patients ≥70 years of age had a nadir of
140/70 mmHg [75]. This supports the need for different
targets for different patient groups, but does suggest that
recent rowing back from lower (especially systolic) tar-
gets in uncomplicated hypertension is probably justified.
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A recent Cochrane review in 2012 assessed the benefit
of pharmacotherapy in patients with mild, uncompli-
cated hypertension (140–149 mmHg systolic and/or 90–
99 mmHg diastolic) [76]. For 7,080 participants, treat-
ment with antihypertensive drugs compared to placebo
did not lead to significant differences in the relative risk
of total mortality, coronary heart disease, stroke or car-
diovascular events, and withdrawals due to adverse
events were increased by antihypertensive drugs [76].
This is reflected in the risk-based approach taken by
NICE and the New Zealand guidelines in terms of only
treating patients with stage 1 hypertension at higher risk
and by JNC 8, albeit controversially in their relaxation of
targets for older people [37, 62, 77].
However, the time taken to bring patients to the
optimum systolic target can also impact on mortality
outcomes. Xu et al. investigated the time to intensifica-
tion of treatment and the time to follow-up for new
medications [78]. Delays in hypertension treatment in-
tensification of 1.4 months or more and delays in BP
follow-up after treatment intensification of 2.7 months
or more resulted in increased likelihood of an acute car-
diovascular event or death by 1.12 and 1.18, respectively.
However, a systolic target of 150 mmHg performed
similarly to one of 140 mmHg, with the greatest risk of
cardiovascular events or death seen at systolic intensifi-
cation targets of 160 mmHg or more and a hazard ratio
of at least 1.21 [78].
Earlier this year, Zanchetti et al. carried out a meta-
analysis on 68 BP lowering trials to try and answer ques-
tions about the effectiveness of current thresholds [79].
They found that all-cause mortality, including stroke,
cardiovascular, coronary heart disease and heart failure,
were all significantly reduced by lowering systolic BP
below 150 mmHg. With the exception of heart fail-
ure, outcomes could be further reduced by reducing
systolic BP to 140 mmHg. Below this, only stroke was
significantly reduced by decreasing systolic BP to
130 mmHg. Similarly, for diastolic BP, a significant
reduction of cardiovascular outcomes could be seen
at a cut-off of <90 mmHg, but only significant reductions
in stroke could be seen for a target of <80 mmHg.
Current target recommendations
NICE reviewed three systematic reviews and 27 prog-
nostic studies to develop their current treatment thresh-
old recommendations [37]. The cut-off points for ABPM
were set lower than those for clinic BP. Evidence for
these thresholds came largely from work comparing
clinic BP and ABPM to cardiovascular outcomes [80, 81].
The Pressioni Arteriose Monitorate e Loro Associazioni
(PAMELA) trial was a landmark study in this area and the
authors predicted that a clinic BP of 140/90 mmHg was
equivalent to a 24-hour ABPM of 125/80 mmHg or a
daytime ABPM of 130/85 mmHg [81]. However, this work
was based on prognostic thresholds and there is very little
evidence for comparable treatment targets between
ABPM and clinic BP. As discussed above, Head et al. ana-
lysed clinic BP and ABPM measurements from patients
referred to hypertension clinics across Australia [34, 80].
The treatment target recommendations for ABPM and
SMBP (Table 1) from the NICE guidelines are largely
based on this work.
NICE suggests an ABPM treatment target of <135/
85 mmHg for patients below 80 years of age and an
ABPM target of <145/85 mmHg for those patients over
80 years [37]. Currently, they are the only guidelines to
specify a common treatment and management threshold
for ABPM with the same thresholds assumed for home
BP monitoring.
The ESH 2013 guidelines suggest a target of <140 mmHg
for all patients under 80 years of age and a diagnostic
target of <90 mmHg. Diabetic patients should be
treated to a diastolic target of <85 mmHg. Patients
over 80 years with a systolic BP ≥160 mmHg should
be treated to a target between 140 and 150 mmHg
according to the evidence [5].
The recent JNC 8 guideline recommended treating
those between 18 and 60 years old to a target of 140/
90 mmHg [62]. However, for those patients above
60 years, they recommended a systolic treatment target
of <150 mmHg. This caused some controversy, but the
committee argued that evidence from the trials they had
considered found little benefit of tighter control leading
to better outcomes [62]. However, many countered that
these recommendations were based on a very small
number of trials which passed the rigorous screening
process, excluding evidence from meta-analysis, and
meaning that this recommendation was almost entirely
based on expert opinion [82].
Conclusion and future directions
Due to its diagnostic accuracy, ABPM seems set to as-
sume greater prominence for the new diagnosis of
hypertension – it is already in place in the NICE and ar-
guably the ESH guidelines [5, 37] and there are strong
recommendations for the USA and Canada to follow suit
[49, 63]. Less developed countries may reasonably con-
tinue with clinic measurement. It is likely that self-
monitoring will also feature strongly and this is seen in
the latest Japanese guidance [83]. There is strong evi-
dence for the use of out-of-office measurements to diag-
nose and manage patients with white coat and masked
hypertension, with important implications for the appro-
priate targeting of treatment.
Outside of primary care, other health professionals,
such as pharmacists, dentists and optometrists, are
starting to have more of a role in monitoring BP.
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There will need to be clear pathways set up between
these organisations and primary care providers in
order to follow-up cases of high BP readings [55].
Self-monitoring is also starting to be used for self-
screening [55] and we may see a role for this in pa-
tients identified as having high-normal BP. Robust
diagnostic guidelines will be needed to advise both
physicians and non-physicians how to obtain accurate
out-of-office measurements. The use of smartwatches
for health tracking may drive greater telemonitoring,
but for the moment cuff-based measurements limit
their use in hypertension.
Table 1 Comparison of recommendations for diagnostic and treatment thresholds between NICE, ESH, JNC and CHEP guidelines
Organisation Year Diagnostic threshold Treatment threshold
UK National Institute for Health and
Care Excellence (NICE)
2011 OBPM diagnostic threshold: ≥140/90 mmHg
(ABPM/HBPM diagnostic threshold:
≥135/85 mmHg)
All patients under 80 yrs: OBPM
< 140/90 mmHg (ABPM/HBPM:
<135/85 mmHg)
OBPM Stage 2 Hypertension ≥160/100 mmHg
(ABPM/HBPM: ≥150/95 mmHg)
Diabetes : OBPM <140/80 mmHg
(or <130/80 mmHg if complications
present)
Older ≥80 yrs: OBPM <150/90 mmHg
(ABPM/HBPM <145/85 mmHg)
European Society of Hypertension (ESH) 2013 OBPM: ≥140 and/or ≥90 All patients under 80 yrs OBPM
<140/90 mmHg
(ABPM Daytime (or awake): ≥135 and/or
≥85 mmHg, ABPM Night-time (or asleep):
≥120 and/or ≥70 mmHg, ABPM 24-h:
≥130 and/or ≥80 mmHg, HBPM: ≥135
and/or ≥85 mmHg)
Diabetes: OBPM <140/85 mmHg
High Risk Patients: OBPM
<130/80 mmHg
Older ≥80 yrs: OBPM <150/90 mmHg
Joint National Committee on Prevention,
Detection, Evaluation and Treatment of
Blood Pressure (JNC 7)
2004 Stage 1 hypertension diagnosis should be
confirmed within 2 months after initial




<130/80 mmHgStage 2 hypertension should be confirmed
within 1 m
≥180/110 mm Hg evaluate and treat
immediately
(ABPM Daytime (or awake): ≥135/85 mmHg,
ABPM Night-time (or asleep): ≥120/75 mmHg)
Routine blood pressure measurements
should be taken
− at least once every 2 years for adults with
<120/80 mmHg
− every year for adults with 120-139/80-89 mmHg
Joint National Committee on Prevention,
Detection, Evaluation and Treatment of
Blood Pressure (JNC 8)
2014 • Guidelines did not address diagnostic
thresholds of hypertension.
Age <60 yrs: OBPM <140/90 mmHg
Diabetes No CKD: OBPM <140/90 mmHg
• The supplementary material recommends
averaging 2–3 measurements at each visit to
establish a diagnosis of hypertension.
CKD present with or without diabetes:
OBPM <140/90 mmHg
Older ≥60 years: OBPM <150/90 mmHg
• Thresholds for pharmacological treatment
were defined.
• HBPM and ABPM were not included.
Canadian Hypertension Education
Program (CHEP)
2015 ABPM Daytime (or awake): ≥135/85 mmHg All ages <80 yrs: OBPM <140/90 mmHg
ABPM 24-h: ≥130/80 mmHg Diabetes: OBPM <130/80 mmHg
HBPM diagnostic threshold: ≥135/85 mmHg) Older ≥80 yrs: OBPM <150 mmHg
OBPM diagnostic threshold:
≥140/90 mmHg averaged across two visits;
≥160/110 mmHg averaged across three visits;
or if ≥140/90 mmHg averaged across five visits
Abbreviations: OBPM office blood pressure measurement, ABPM ambulatory blood pressure measurement, HBPM home blood pressure measurement, CKD chronic
kidney disease
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Measurement of blood pressure is well captured by
the guidelines, but what is less clear is how to ensure
adequate population screening. Further studies should
seek to establish optimum rescreening intervals, alterna-
tive ways to gain full population coverage and methods
to identify those at greatest risk.
Many trials have shown that controlling blood pres-
sure is an important way of reducing heart disease and
stroke [68, 74, 84, 85]. Blood pressure targets are an es-
sential clinical tool for guiding control of blood pressure.
However, questions about the optimum targets remain,
particularly for patient subpopulations, such as the eld-
erly, those with high cardiovascular risk and certain eth-
nic groups [86]. Studies in this area should focus on the
optimum BP threshold to initiate treatment, but also
perhaps when to reduce treatment, particularly in the
context of polypharmacy [87].
Overall, the mainstay of hypertension diagnosis and
monitoring is likely to remain systematically identifying
and then treating patients to fairly conventional targets,
with use of out-of-office monitoring for both diagnosis
and management. Ensuring physicians do not succumb
to clinical inertia is probably as important as the actual
methods and targets used [88].
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